Literature DB >> 21327030

Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

V K Viswanathan1, M J Mallozzi, Gayatri Vedantam.   

Abstract

Clostridium difficile infection (CDI) is the primary cause of antibiotic-associated diarrhea and is a significant nosocomial disease. In the past ten years, variant toxin-producing strains of C. difficile have emerged, that have been associated with severe disease as well as outbreaks worldwide. This review summarizes current information on C. difficile pathogenesis and disease, and highlights interventions used to combat single and recurrent episodes of CDI.

Entities:  

Year:  2010        PMID: 21327030      PMCID: PMC3023605          DOI: 10.4161/gmic.1.4.12706

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  142 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

2.  UK launches inquiry into Clostridium difficile outbreak.

Authors:  Vittal Katikireddi
Journal:  CMAJ       Date:  2005-07-19       Impact factor: 8.262

3.  Antibiotic resistance of Clostridium difficile isolates.

Authors:  A Dworczyński; B Sokół; F Meisel-Mikołajczyk
Journal:  Cytobios       Date:  1991

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Regulated transcription of Clostridium difficile toxin genes.

Authors:  B Dupuy; A L Sonenshein
Journal:  Mol Microbiol       Date:  1998-01       Impact factor: 3.501

6.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 7.  Typing of Clostridium difficile.

Authors:  J S Brazier
Journal:  Clin Microbiol Infect       Date:  2001-08       Impact factor: 8.067

8.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Clostridium difficile in broiler chickens sold at market places in Zimbabwe and their antimicrobial susceptibility.

Authors:  Clifford Simango; Silas Mwakurudza
Journal:  Int J Food Microbiol       Date:  2008-04-01       Impact factor: 5.277

10.  Human alpha-defensins inhibit Clostridium difficile toxin B.

Authors:  Torsten Giesemann; Gregor Guttenberg; Klaus Aktories
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

View more
  41 in total

1.  Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.

Authors:  J A Leeds; M Sachdeva; S Mullin; J Dzink-Fox; M J Lamarche
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology.

Authors:  Andrew E Clark; Erin J Kaleta; Amit Arora; Donna M Wolk
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.

Authors:  Michael C Abt; Brittany B Lewis; Silvia Caballero; Huizhong Xiong; Rebecca A Carter; Bože Sušac; Lilan Ling; Ingrid Leiner; Eric G Pamer
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

4.  Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT).

Authors:  Panagiotis Papatheodorou; Jan E Carette; George W Bell; Carsten Schwan; Gregor Guttenberg; Thijn R Brummelkamp; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 5.  Use of the Microbiome in the Practice of Epidemiology: A Primer on -Omic Technologies.

Authors:  Betsy Foxman; Emily T Martin
Journal:  Am J Epidemiol       Date:  2015-05-29       Impact factor: 4.897

6.  Evaluation of Risk Factors for Clostridium difficile Infection Based on Immunochromatography Testing and Toxigenic Culture Assay.

Authors:  Toshio Ohshima; Takako Osaki; Yukari Yamamoto; Satomi Asai; Hayato Miyachi; Shigeru Kamiya
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

Review 7.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

8.  Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

9.  Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links.

Authors:  Johann Peltier; Pascal Courtin; Imane El Meouche; Ludovic Lemée; Marie-Pierre Chapot-Chartier; Jean-Louis Pons
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

10.  Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.

Authors:  Simon A Hirota; Vadim Iablokov; Sarah E Tulk; L Patrick Schenck; Helen Becker; Jimmie Nguyen; Samir Al Bashir; Tanis C Dingle; Austin Laing; Jianrui Liu; Yan Li; Jeff Bolstad; George L Mulvey; Glen D Armstrong; Wallace K MacNaughton; Daniel A Muruve; Justin A MacDonald; Paul L Beck
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.